Literature DB >> 16455959

Cutting edge: an alternative pathway of CD4+ T cell differentiation is induced following activation in the absence of gamma-chain-dependent cytokine signals.

Shane R Mayack1, Leslie J Berg.   

Abstract

This report addresses the role of gamma-chain cytokine signals in regulating CD4(+) T cell differentiation following activation. Using murine CD4(+) T cells lacking the Jak3 tyrosine kinase, we show that activation of these cells in the absence of gamma-chain-dependent cytokine signals induces an alternative pathway of T cell differentiation. Specifically, activated Jak3(-/-) CD4(+) T cells produce IL-10, TGF-beta, and IFN-gamma, but not IL-2 or IL-4, and are unable to proliferate in vitro. In addition, Jak3(-/-) CD4(+) T cells express high levels of programmed death-1 and lymphocyte activation gene-3 and modestly suppress the proliferation of wild-type CD4(+) T cells in coculture assays. Together, these features demonstrate a striking similarity between Jak3(-/-) CD4(+) T cells and the regulatory T cells that have been shown to suppress immune responses in vitro and in vivo. We conclude that Jak3 is a critical component of signaling pathways that regulate T cell differentiation into effector vs regulatory lineages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455959     DOI: 10.4049/jimmunol.176.4.2059

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.

Authors:  Marina Cetkovic-Cvrlje; Marin Olson; Ketaki Ghate
Journal:  Cell Mol Immunol       Date:  2012-06-25       Impact factor: 11.530

2.  Nonredundant roles for Stat5a/b in directly regulating Foxp3.

Authors:  Zhengju Yao; Yuka Kanno; Marc Kerenyi; Geoffrey Stephens; Lydia Durant; Wendy T Watford; Arian Laurence; Gertraud W Robinson; Ethan M Shevach; Richard Moriggl; Lothar Hennighausen; Changyou Wu; John J O'Shea
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

Review 3.  Therapeutic targeting of Janus kinases.

Authors:  Marko Pesu; Arian Laurence; Nandini Kishore; Samuel H Zwillich; Gary Chan; John J O'Shea
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 4.  Janus kinase 3: the controller and the controlled.

Authors:  Wei Wu; Xiao-Hong Sun
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2011-11-29       Impact factor: 3.848

Review 5.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

6.  Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients.

Authors:  C John Sperati; Rulan S Parekh; Yvette Berthier-Schaad; Bernard G Jaar; Laura Plantinga; Nancy Fink; Neil R Powe; Michael W Smith; Josef Coresh; W H Linda Kao
Journal:  Am J Kidney Dis       Date:  2009-03-12       Impact factor: 8.860

Review 7.  New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation.

Authors:  Lai Wei; Arian Laurence; John J O'Shea
Journal:  Semin Cell Dev Biol       Date:  2008-07-30       Impact factor: 7.727

Review 8.  Cytokine signaling modules in inflammatory responses.

Authors:  John J O'Shea; Peter J Murray
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

Review 9.  Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?

Authors:  Jochen Huehn; Julia K Polansky; Alf Hamann
Journal:  Nat Rev Immunol       Date:  2009-02       Impact factor: 53.106

10.  IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells.

Authors:  Cristina Penaranda; Wilson Kuswanto; Jerry Hofmann; Rupert Kenefeck; Parth Narendran; Lucy S K Walker; Jeffrey A Bluestone; Abul K Abbas; Hans Dooms
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.